BRIEF-Vanda Announces Submission Of Biologics License Application To The FDA For Imsidolimab For The Treatment Of Generalized Pustular Psoriasis

Reuters12-15

Dec 15 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O :

VANDA ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO THE FDA FOR IMSIDOLIMAB FOR THE TREATMENT OF GENERALIZED PUSTULAR PSORIASIS
VANDA PHARMACEUTICALS: PRIORITY REVIEW WOULD ESTABLISH 6-MONTH REVIEW CYCLE, POTENTIAL IMSIDOLIMAB FDA APPROVAL FOR GPP TREATMENT AS EARLY AS MID-2026

Source text: ID:nPn1J0jnCa

Further company coverage: VNDA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591964689?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 20:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591964689","market":"us","top_or_hot":-1,"title":"BRIEF-Vanda Announces Submission Of Biologics License Application To The FDA For Imsidolimab For The Treatment Of Generalized Pustular Psoriasis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Vanda Announces Submission Of Biologics License Application To The FDA For Imsidolimab For The Treatment Of Generalized Pustular Psoriasis</title></head><body><p><span>Dec 15 (Reuters)</span><span> - </span>Vanda Pharmaceuticals Inc <span>VNDA.O</span> : </p><ul><li><p>VANDA ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO THE FDA FOR IMSIDOLIMAB FOR THE TREATMENT OF GENERALIZED PUSTULAR PSORIASIS</p></li><li><p>VANDA PHARMACEUTICALS: PRIORITY REVIEW WOULD ESTABLISH 6-MONTH REVIEW CYCLE, POTENTIAL IMSIDOLIMAB FDA APPROVAL FOR GPP TREATMENT AS EARLY AS MID-2026</p></li></ul><p>Source text: <span>ID:nPn1J0jnCa</span></p><p>Further company coverage: <span>VNDA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Vanda Announces Submission Of Biologics License Application To The FDA For Imsidolimab For The Treatment Of Generalized Pustular Psoriasis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Vanda Announces Submission Of Biologics License Application To The FDA For Imsidolimab For The Treatment Of Generalized Pustular Psoriasis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-15 20:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Vanda Announces Submission Of Biologics License Application To The FDA For Imsidolimab For The Treatment Of Generalized Pustular Psoriasis</title></head><body><p><span>Dec 15 (Reuters)</span><span> - </span>Vanda Pharmaceuticals Inc <span>VNDA.O</span> : </p><ul><li><p>VANDA ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO THE FDA FOR IMSIDOLIMAB FOR THE TREATMENT OF GENERALIZED PUSTULAR PSORIASIS</p></li><li><p>VANDA PHARMACEUTICALS: PRIORITY REVIEW WOULD ESTABLISH 6-MONTH REVIEW CYCLE, POTENTIAL IMSIDOLIMAB FDA APPROVAL FOR GPP TREATMENT AS EARLY AS MID-2026</p></li></ul><p>Source text: <span>ID:nPn1J0jnCa</span></p><p>Further company coverage: <span>VNDA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA7M5FCM:1","article_id":"2591964689","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591964689","pubTimestamp":1765801306,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Vanda Announces Submission Of Biologics License Application To The FDA For Imsidolimab For The Treatment Of Generalized Pustular PsoriasisDec 15 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O : VA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VNDA":"万达生物制药","ANAB":"Anaptysbio Inc"},"translate_title":"BRIEF-Vanda宣布向FDA提交Imsidolimab治疗泛发性脓疱型银屑病的生物制剂许可申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANAB":0.9,"VNDA":0.9},"content_text":"BRIEF-Vanda Announces Submission Of Biologics License Application To The FDA For Imsidolimab For The Treatment Of Generalized Pustular PsoriasisDec 15 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O : VANDA ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO THE FDA FOR IMSIDOLIMAB FOR THE TREATMENT OF GENERALIZED PUSTULAR PSORIASISVANDA PHARMACEUTICALS: PRIORITY REVIEW WOULD ESTABLISH 6-MONTH REVIEW CYCLE, POTENTIAL IMSIDOLIMAB FDA APPROVAL FOR GPP TREATMENT AS EARLY AS MID-2026Source text: ID:nPn1J0jnCaFurther company coverage: VNDA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591964689","isCrawlerRequest":true}